HEM Pharma Cash Flow Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Net Income	-23,842	-7,646
Depreciation & Amortization	2,595	2,422
Loss (Gain) From Sale of Assets	7.02	-
Asset Writedown & Restructuring Costs	534.93	-
Loss (Gain) From Sale of Investments	-30.47	-24.89
Stock-Based Compensation	929.21	915.56
Provision & Write-off of Bad Debts	0.14	-
Other Operating Activities	7,814	418.39
Change in Accounts Receivable	2,708	-2,568
Change in Inventory	-504.96	-781.57
Change in Accounts Payable	410.61	549.43
Change in Other Net Operating Assets	1,033	-964.77
Operating Cash Flow	-8,345	-7,680
Capital Expenditures	-9,755	-4,687
Sale of Property, Plant & Equipment	16.18	-
Cash Acquisitions	-106.19	-
Sale (Purchase) of Intangibles	-229.87	-110.97
Investment in Securities	4,504	-4,675
Other Investing Activities	-0	-
Investing Cash Flow	-5,571	-9,473
Short-Term Debt Issued	1,400	-
Long-Term Debt Issued	19,218	-
Total Debt Issued	20,618	-
Long-Term Debt Repaid	-890.94	-324.36
Net Debt Issued (Repaid)	19,727	-324.36
Issuance of Common Stock	1,707	16,512
Other Financing Activities	-8.06	-915.47
Financing Cash Flow	21,425	15,272
Foreign Exchange Rate Adjustments	1.31	3.91
Miscellaneous Cash Flow Adjustments	-	-0
Net Cash Flow	7,511	-1,877
Free Cash Flow	-18,100	-12,367
Free Cash Flow Margin	-139.45%	-82.08%
Free Cash Flow Per Share	-2572.76	-1945.77
Cash Interest Paid	418.68	258.79
Cash Income Tax Paid	20.7	-22.47
Levered Free Cash Flow	4,409	-
Unlevered Free Cash Flow	4,814	-
Change in Working Capital	3,647	-3,765

Source: S&P Global Market Intelligence. Standard template. Financial Sources.